- Home
- BDRX vs CHEK Comparison
BDRX vs CHEK Comparison
Compare BDRX & CHEK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BDRX
- CHEK
- Stock Information
- Founded
- BDRX 2000
- CHEK 2004
- Country
- BDRX United Kingdom
- CHEK Israel
- Employees
- BDRX N/A
- CHEK N/A
- Industry
- BDRX Biotechnology: Pharmaceutical Preparations
- CHEK Medical Electronics
- Sector
- BDRX Health Care
- CHEK Health Care
- Exchange
- BDRX Nasdaq
- CHEK Nasdaq
- Market Cap
- BDRX 4.3M
- CHEK 4.5M
- IPO Year
- BDRX N/A
- CHEK 2015
- Fundamental
- Price
- BDRX $6.60
- CHEK $0.64
- Analyst Decision
- BDRX
- CHEK
- Analyst Count
- BDRX 0
- CHEK 0
- Target Price
- BDRX N/A
- CHEK N/A
- AVG Volume (30 Days)
- BDRX 33.0K
- CHEK 26.6K
- Earning Date
- BDRX 09-29-2025
- CHEK 09-02-2025
- Dividend Yield
- BDRX N/A
- CHEK N/A
- EPS Growth
- BDRX N/A
- CHEK N/A
- EPS
- BDRX N/A
- CHEK N/A
- Revenue
- BDRX N/A
- CHEK N/A
- Revenue This Year
- BDRX N/A
- CHEK N/A
- Revenue Next Year
- BDRX N/A
- CHEK N/A
- P/E Ratio
- BDRX N/A
- CHEK N/A
- Revenue Growth
- BDRX N/A
- CHEK N/A
- 52 Week Low
- BDRX $5.85
- CHEK $0.56
- 52 Week High
- BDRX $160.00
- CHEK $3.04
- Technical
- Relative Strength Index (RSI)
- BDRX 36.03
- CHEK 37.53
- Support Level
- BDRX $6.31
- CHEK $0.64
- Resistance Level
- BDRX $7.24
- CHEK $0.68
- Average True Range (ATR)
- BDRX 0.39
- CHEK 0.04
- MACD
- BDRX 0.04
- CHEK 0.00
- Stochastic Oscillator
- BDRX 30.85
- CHEK 40.31
About BDRX Biodexa Pharmaceuticals plc
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.
About CHEK Check-Cap Ltd.
Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.